NCT00323869 - Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Lung CancerNon-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Bevacizumab

Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody

DRUG

Gemcitabine

Nucleoside analog

DRUG

Carboplatin

Alkylating agent

Trial Locations (3)

Stanford University School of Medicine, Stanford

Santa Clara Valley Medical Center, San Jose

VA Palo Alto Healthcare System, Palo Alto